nach oben

Erschienen in:

01.12.2011 | Original Article

The Role of Integrated F-18-FDG-PET Scanning in the Detection of M1 Disease in Oesophageal Adenocarcinoma and Impact on Clinical Management

verfasst von: Soumil Vyas, Sheraz R. Markar, Lydia Iordanidou, Samantha Read, David Stoker, Majid Hashemi, Ian Mitchell, Mark Winslet, Jamshed Bomanji

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The aim of this study was to evaluate the efficacy of F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) scanning in the staging of oesophageal adenocarcinoma.

Methods

One hundred four patients with biopsy-proven adenocarcinoma underwent ¹⁸F-FDG-PET scan. FDG avid lesions were further investigated to their diagnostic conclusion.

Results

Nineteen patients (18.26%) were found to have non-loco-regional FDG uptake. Of the patients, 3.84% were found to have M1 disease and 7.69% were found to have a second primary tumour. The sensitivity and specificity of FDG-PET scanning to detect metastatic disease in our series was 57.14% and 84.53%, respectively. The overall diagnostic accuracy was 82.69%.

Conclusions

PET scanning improves staging and prevents unnecessary surgery in patients with M1 disease. It represents a good adjunct to computed tomography scanning and endoscopic ultrasound in the staging of oesophageal adenocarcinoma. The detection of asymptomatic coexisting synchronous cancers is an added benefit provided by PET scanning over similar diagnostic modalities.

Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97:142–6.PubMedCrossRef

Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of oesophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049–53.PubMedCrossRef

Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 549–55.PubMedCrossRef

El-Serag HB. The epidemic of oesophageal adenocarcinoma. Gastroenterol Clin North Am 2002; 31:421–40.PubMedCrossRef

Stein HJ, Brücher BL, Sendler A, Siewert JR. Esophageal cancer: patient evaluation and pre-treatment staging. Surg Oncol. 2001 Nov;10(3):103–11. Review.PubMedCrossRef

Pfau PR, Perlman SB, Stanko P, Frick TJ, Gopal DV, Said A, Zhang Z, Weigel T. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc.2007 Mar;65(3):377–84.PubMedCrossRef

Omloo JM, Sloof GW, Boellaard R, Hoekstra OS, Jager PL, van Dullemen HM, Fockens P, Plukker JT, van Lanschot JJ. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy. 2008 Jun;40(6):464–71PubMedCrossRef

van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for esophageal cancer: a meta-analysis. Br J Cancer. 2008 Feb 12;98(3):547–57. Epub 2008 Jan 22.PubMedCrossRef

MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol 2009;91(1):85–94PubMedCrossRef

10.

Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan TS, Macapinlac HA, Erasmus JJ.PET/CT of esophageal Cancer: its role in clinical management. Radiographics. 2007 Nov-Dec; 27(6):1635–52. Review.PubMedCrossRef

11.

Liberale G, Van Laethem JL, Gay F, Goldman S, Nagy N, Coppens E, Gelin M, El Nakadi I. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol. 2004 Nov;30(9):942–7.PubMedCrossRef

12.

Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000 Sep 15;18(18):3202–10.PubMed

13.

van Westreenen HL, Heeren PA, van Dullemen HM, van der Jagt EJ, Jager PL, Groen H, Plukker JT. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg. 2005 Jan;9(1):54–61.PubMedCrossRef

14.

Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, Jager PL, Van Eck-Smit BL, Plukker JT, van Lanschot JJ, Sloof GW. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology. 2005 Sep;236(3):841–51. Review.PubMedCrossRef

15.

van Westreenen HL, Heeren PA, Jager PL, van Dullemen HM, Groen H, Plukker JT. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol. 2003 Nov;10(9):1100–5.PubMedCrossRef

16.

Gillies RS, Middleton MR, Maynard ND, Bradley KM, Gleeson FV. Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. Eur Radiol. 2011 Feb;21(2):274–80PubMedCrossRef

17.

Gospodarowicz M, Wittekind C, Sobin L. Esophagus. In: Wittekind C, Sobin L (eds) UICC—TNM Classification of malignant tumours, 7th edn. Wiley, New York (2009)

18.

Choi JY, Lee KS, Kwon OJ, Shim YM, Baek CH, Park K, Lee KH, Kim BT. Improved detection of second primary cancer using integrated [¹⁸F]fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol. 2005 Oct 20;23(30):7654–9.PubMedCrossRef

19.

Thompson WM, Halvorsen RA Jr: Staging esophageal carcinoma II: CT and MRI. Semin Oncol 21:447–452, 1994PubMed

20.

van Westreenen HL, Westerterp M, Bossuyt PM, Pruim J, Sloof GW, van Lanschot JJ, Groen H, Plukker JT. Systematic review of the staging performance of ¹⁸F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004 Sep 15;22(18):3805–12. Review.PubMedCrossRef

21.

Rice TW: Clinical staging of esophageal carcinoma: CT, EUS, and PET. Chest Surg Clin N Am 10:471–485, 2000PubMed

22.

Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, Siegel BA, Cooper JD. Improvement in Staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997;64:770 –7PubMedCrossRef

23.

Peters JH, Hoeft SF, Heimbucher J, Bremner RM, DeMeester TR, Bremner CG, Clark GW, Kiyabu M, Parisky Y. Selection of patients for curative or palliative resection of esophageal cancer based on preoperative endoscopic ultrasonography. Arch Surg. 1994 May;129(5):534–9.PubMed

24.

Chandawarkar RY, Kakegawa R, Fujita H, Yamana H, Hayabuthi N. Comparative analysis of imaging modalities in the preoperative assessment of nodal metastasis in esophageal cancer. J Surg Oncol 1996;61:214–7.PubMedCrossRef

25.

Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Thoracoscopic staging and surgical therapy for esophageal cancer. Chest 1995; 107:218S–23SPubMedCrossRef

26.

van Westreenen HL, Westerterp M, Sloof GW, Groen H, Bossuyt PM, Jager PL,Comans EF, van Dullemen HM, Fockens P, Stoker J, van der Jagt EJ, van Lanschot JJ, Plukker JT. Limited additional value of positron emission tomography in staging oesophageal cancer.Br J Surg. 2007 Dec;94(12):1515–20PubMedCrossRef

27.

Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996 Dec;23(12):1641–74. Review.PubMedCrossRef

28.

Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR. PET and [¹⁸F]-FDG in oncology: a clinical update. Nucl Med Biol 1996;23:717–35.PubMedCrossRef

29.

Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30:150–185PubMedCrossRef

30.

Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N, Endo K. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005 Jan 1;103(1):148–56.PubMedCrossRef

31.

Luketich JD, Schauer PR, Meltzer CC, Landreneau RJ, Urso GK, Townsend DW, Ferson PF, Keenan RJ, Belani CP. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997 Sep;64(3):765–9.PubMedCrossRef

32.

Bar-Shalom R, Guralnik L, Tsalic M, Leiderman M, Frenkel A, Gaitini D, Ben-Nun A, Keidar Z, Israel O. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging. 2005 Aug;32(8):918–24. Epub 2005 Apr 19.PubMedCrossRef

33.

Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer. 1998 Aug;78(4):521–7.PubMedCrossRef

34.

Ott K, Weber W, Siewert JR. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus. 2006;19(6):433–42.PubMedCrossRef

35.

Wallace MB, Nietert PJ, Earle C, Krasna MJ, Hawes RH, Hoffman BJ, Reed CE. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg. 2002 Oct;74(4):1026–32.PubMedCrossRef

36.

Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 2002;137: 1001–7.PubMedCrossRef

37.

Bruzzi JF, Truong MT, Macapinlac H, Munden RF, Erasmus JJ. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases. Curr Probl Diagn Radiol 2007;36:21–29.PubMedCrossRef

38.

van Westreenen HL, Westerterp M, Jager PL, van Dullemen HM, Sloof GW, Comans EF, van Lanschot JJ, Wiggers T, Plukker JT. Synchronous primary neoplasms detected on ¹⁸F-FDG PET in staging of patients with esophageal cancer. J Nucl Med. 2005 Aug;46(8):1321–5PubMed

39.

Kumagai Y, Kawano T, Nakajima Y, et al. Multiple primary cancers associated with esophageal carcinoma. Surg Today 2001;31:872–876.PubMedCrossRef

40.

Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology. 2004 Feb;230(2):417–22. Epub 2003 Dec 29.PubMedCrossRef

41.

Zhuang H, Hickeson M, Chacko TK, Duarte PS, Nakhoda KZ, Feng Q, Alavi A. Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules. Clin Nucl Med. 2002 Sep;27(9):628–32.PubMedCrossRef

42.

Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology. 2002 Sep;224(3):783–7.PubMedCrossRef

43.

Kagei K, Hosokawa M, Shirato H, Kusumi T, Shimizu Y, Watanabe A, Ueda M. Efficacy of intense screening and treatment for synchronous second primary cancers in patients with esophageal cancer. Jpn J Clin Oncol. 2002 Apr;32(4):120–7.PubMedCrossRef

44.

Bollschweiler E, Schloesser T, Leers J, Vallböhmer D, Schäfer H, Hölscher AH. High prevalence of colonic polyps in white males with esophageal adenocarcinoma. Dis Colon Rectum. 2009 Feb;52(2):299–304.PubMedCrossRef

45.

Meyers BF, Downey RJ, Decker PA, Keenan RJ, Siegel BA, Cerfolio RJ, Landreneau RJ, Reed CE, Balfe DM, Dehdashti F, Ballman KV, Rusch VW, Putnam JB Jr; American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg. 2007 Mar;133(3):738–45.PubMedCrossRef

46.

Heeren PA, Jager PL, Bongaerts F, van Dullemen H, Sluiter W, Plukker JT. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med. 2004 Jun;45(6):980–7.PubMed

47.

Walker AJ, Spier BJ, Perlman SB, Stangl JR, Frick TJ, Gopal DV, Lindstrom MJ, Weigel TL, Pfau PR. Integrated PET/CT fusion imaging and endoscopic ultrasound in the pre-operative staging and evaluation of esophageal cancer. Mol Imaging Biol. 2011 Feb;13(1):166–71.PubMedCrossRef

48.

Thurau K, Palmes D, Franzius C, Minin E, Senninger N, Juergens KU, Bruewer M. Impact of PET-CT on primary staging and response control on multimodal treatment of esophageal cancer. World J Surg. 2011 Mar;35(3):608–16PubMedCrossRef

Titel: The Role of Integrated F-18-FDG-PET Scanning in the Detection of M1 Disease in Oesophageal Adenocarcinoma and Impact on Clinical Management
verfasst von: Soumil Vyas
Sheraz R. Markar
Lydia Iordanidou
Samantha Read
David Stoker
Majid Hashemi
Ian Mitchell
Mark Winslet
Jamshed Bomanji
Publikationsdatum: 01.12.2011
Verlag: Springer-Verlag
Erschienen in: Journal of Gastrointestinal Surgery / Ausgabe 12/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-011-1686-4

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2011

Defining a High-Risk Subgroup of Pathological T2N0 Gastric Cancer by Prognostic Risk Stratification for Adjuvant Therapy

Prealbumin Levels as a Useful Marker for Predicting Infectious Complications After Gastric Surgery

Subject Review: Pancreatic Ductal Adenocarcinoma in the Setting of Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Gene: Case Report and Review of the Literature

Long-Term Survival Results of Surgery Alone Versus Surgery plus UFT (Uracil and Tegafur)-Based Adjuvant Therapy in Patients with Stage II Colon Cancer

Jejunal Subserosal Hematoma in an 11-Year-Old Boy

Intraoperative Real-Time Cholangiography and C-tube Drainage in Donor Hepatectomy Reduce Biliary Tract Complications

Update Chirurgie